BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 15.0% in November

BioAtla, Inc. (NASDAQ:BCAB) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 4,140,000 shares, a decrease of 15.0% from the October 31st total of 4,870,000 shares. Based on an average daily trading volume, of 1,190,000 shares, the days-to-cover ratio is presently 3.5 days.

Hedge Funds Weigh In On BioAtla

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of BioAtla by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock valued at $7,221,000 after purchasing an additional 17,667 shares during the period. AQR Capital Management LLC bought a new stake in BioAtla in the second quarter worth approximately $872,000. Scion Asset Management LLC acquired a new position in BioAtla in the second quarter valued at approximately $869,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of BioAtla by 5.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after buying an additional 28,133 shares in the last quarter. Finally, Bank of Montreal Can grew its position in shares of BioAtla by 55.1% during the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock worth $554,000 after buying an additional 143,521 shares during the period. Institutional investors own 77.23% of the company’s stock.

BioAtla Stock Performance

Shares of BCAB opened at $1.68 on Friday. The business has a 50-day moving average of $1.88 and a 200-day moving average of $1.77. BioAtla has a 1 year low of $1.14 and a 1 year high of $4.02.

BioAtla (NASDAQ:BCAB) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The firm had revenue of $11.00 million for the quarter. During the same period in the previous year, the company earned ($0.70) earnings per share. Sell-side analysts predict that BioAtla will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. HC Wainwright downgraded shares of BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of BioAtla in a report on Monday, September 16th.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.